<DOC>
	<DOCNO>NCT01802346</DOCNO>
	<brief_summary>This randomized phase II trial study well control low calorie diet work reduce side effect increase response chemotherapy patient breast prostate cancer . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Eating special diet low calorie may reduce side effect chemotherapy improve response treatment</brief_summary>
	<brief_title>Controlled Low Calorie Diet Reducing Side Effects Increasing Response Chemotherapy Patients With Breast Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To obtain preliminary estimate impact restrict diet toxicity efficacy chemotherapy breast prostate cancer . II . To evaluate compliance control diet intervention . III . To investigate change plasma insulin , glucose , insulin-like growth factor 1 ( IGF1 ) IGF bind protein ( IGFBP ) level subject consume restrict diet compare control . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients eat special low-calorie diet 3 day prior chemotherapy , 12 week chemotherapy , 24 hour chemotherapy . Patients provide meal food consume maintain diary food consume appropriate amount . Patients meet study dietician within 3 week enrollment prior , day , first course chemotherapy study start subsequent course . ARM II : Patients eat normal diet receive dietary advice may include consultation nutritionist . Patients maintain diary food consume appropriate amount .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm breast cancer chemotherapy AC ( doxorubicin plus cyclophosphamide ) utilized neoadjuvant adjuvant setting OR metastatic prostate adenocarcinoma Docetaxel administer Body mass index ( BMI ) &gt; = 18.5 Subjects need measurable evaluable disease ; chemotherapy may administer neoadjuvant , adjuvant , metastatic set Prior therapy : Breast cancer subject may receive prior chemotherapy , exception curativeintent chemotherapy separate malignancy 3 year ago Prostate cancer subject may receive prior treatment metronomic cyclophosphamide consider antiangiogenic/immunomodulatory cytotoxic Prostate cancer subject may receive 2nd course docetaxel provide ** The first course result PSA response ( &gt; 30 % reduction prostate specific antigen [ PSA ] and/or improvement radiographic finding pain ) last dose &gt; = 9 month ago Prior Radiotherapy allow , provide least 2 week elapse completion radiotherapy initiation protocol treatment Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2x upper limit normal ( ULN ) Absolute neutrophil count ( ANC ) &gt; 1500 Platelets ( plts ) &gt; 90,000 Premenopausal woman must negative pregnancy test must agree use barrier contraception throughout study period Diabetes Mellitus Peripheral Neuropathy &gt; = grade 1 Prior therapy inhibitor IGF1 Concurrent use somatostatin Significant food allergy would make subject unable consume food provide ( ex : shellfish , soy egg allergy )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>